BioSpace News Archive

Xilio Therapeutics, Inc. announced that the company will participate virtually in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 2:55 p.m. ET.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the WaveForm TA (TLIF Articulating) Interbody System.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will participate in the following upcoming investor conferences.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6th in Barcelona, Spain.

Champions Oncology, Inc. will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close.

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.

Evolus, Inc. announced that the Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 169,158 shares of Evolus common stock and 36,443 restricted stock units to Sandra Beaver, the company’s new Chief Financial Officer.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 6th Annual Best Ideas Growth (BIG6) Conference in New York, on September 14, 2022.

Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that management will participate in two investor conferences in September.